Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.

doi:10.1080/10428194.2023.2185091

Article

Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.

Leukemia & lymphoma - 1 May 2023

Ramia de Cap Maximiliano, Wu Leo P, Hirt Christian, Pihan German A, Patel Sanjay S, Tam Wayne, Bueso-Ramos Carlos E, Kanagal-Shamanna Rashmi, Raess Philipp W, Siddon Alexa, Narayanan Damodaran, Morgan Elizabeth A, Pinkus Geraldine S, Mason Emily F, Hsi Eric D, Rogers Heesun J, Toth Laura, Foucar Kathryn, Hurwitz Stephanie N, Bagg Adam, Rets Anton, George Tracy I, Orazi Attilio, Arber Daniel A, Hasserjian Robert P, Weinberg Olga K

Abstract excerpt

Myeloid sarcoma (MS) is currently considered equivalent to de novo acute myeloid leukemia (AML); however, the relationship between these entities is poorly understood. This retrospective multi-institutional cohort study compared 43 MS with NPM1 mutation to 106 AML with NPM1 mutation. Compared to AML, MS had more frequent cytogenetic abnormalities including complex karyotype (p = .009 and p = .007, respectively)...

Topics

Join the communities discussing this publication.

Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.

Abstract excerpt

Topics

Discuss the evidence

Related research